CG Oncology, Inc. Common stock
$74.12
$1.57 (+2.16%)
$72.66Day Range$74.59
Key Statistics
Market Cap
$6.43B
Shares Outstanding
88.6M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jan 25, 2024
Round Lot
100
Locale
US
Trading Data
Day Open
$72.66
Day High
$74.59
Day Low
$72.66
Volume
795.7K
VWAP
$73.84
Prev Close
$72.55
Transactions
--
Acc. Volume
--
About CG Oncology, Inc. Common stock
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 2836142 employees3000 PEGASUS PARK DRIVE, DALLAS, TX, 75247(949) 409-3700IPO Jan 25, 2024US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001991792
- Composite FIGI
- BBG00YHKK4Q3
- Share Class FIGI
- BBG00YHKK4R2
- Ticker Root
- CGON
- SIC Code
- 2836
About CG Oncology, Inc. Common stock (CGON) Stock
CG Oncology, Inc. Common stock (CGON) closed the 2026-09-16 session at $74.12, up 2.16% versus the previous close (+1.57). The stock opened at $72.66 and traded between $72.66 and $74.59 during that session. Session trading volume was 796K shares. The volume-weighted average price (VWAP) is $73.84.
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
CG Oncology, Inc. Common stock has a market capitalization of $6.43 billion. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. CGON is listed on the XNAS exchange. The company employs approximately 142 people. CG Oncology, Inc. Common stock is headquartered in DALLAS, TX. The recorded listing date is 2024-01-25.
On this page you can find market CGON stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.